Adjuvant Therapy in Stage I Testicular Cancer: Surveillance for All

Stephan Brönimann; Nirmish Singla

doi:10.1016/j.euf.2024.05.017

Adjuvant Therapy in Stage I Testicular Cancer: Surveillance for All

Eur Urol Focus. 2024 May;10(3):357-358. doi: 10.1016/j.euf.2024.05.017. Epub 2024 Jun 1.

Authors

Stephan Brönimann¹, Nirmish Singla²

Affiliations

¹ Department of Urology, The Brady Urological Institute, The Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Oncology, The Brady Urological Institute, The Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Urology, Medical University of Vienna, Vienna, Austria.
² Department of Urology, The Brady Urological Institute, The Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Oncology, The Brady Urological Institute, The Johns Hopkins University School of Medicine, Baltimore, MD, USA. Electronic address: nsingla2@jhmi.edu.

PMID: 38825407
DOI: 10.1016/j.euf.2024.05.017

Abstract

Given the remarkably high cure rates for clinical stage (CS) I testicular cancer, the toxicities and risks of adjuvant treatments, the cost effectiveness of surveillance, and the lack of reliable biomarkers to predict relapse, surveillance should be recommended for all patients with CS I testicular cancer.

MeSH terms

Chemotherapy, Adjuvant
Humans
Male
Neoplasm Recurrence, Local
Neoplasm Staging*
Neoplasms, Germ Cell and Embryonal / pathology
Neoplasms, Germ Cell and Embryonal / therapy
Orchiectomy
Testicular Neoplasms* / pathology
Testicular Neoplasms* / therapy
Watchful Waiting